Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an update.
Atomo Diagnostics Limited has announced a new securities purchase plan, offering up to 30,303,030 ordinary fully paid shares to eligible investors on the ASX register as at 27 March 2026. The offer, which closes on 8 May 2026 with an issue date of 15 May 2026, also includes up to 15,151,515 options expiring 2.5 years from issue and exercisable at $0.045, providing the company with additional potential future capital and giving shareholders a structured opportunity to increase their exposure to the business.
The securities purchase plan is part of Atomo Diagnostics’ broader capital-raising strategy, aimed at strengthening its balance sheet and supporting ongoing operational and growth objectives in the diagnostics sector. By combining new equity with attached options, the company is positioning itself to secure immediate funding while also setting up a mechanism for further capital inflows if the options are exercised, which may influence its market liquidity and ownership structure over time.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an ASX-listed medical diagnostics company focused on rapid testing technologies. The company issues ordinary fully paid shares and related options as part of its capital management and investor funding activities in the listed equity market.
Average Trading Volume: 2,349,202
Technical Sentiment Signal: Hold
Current Market Cap: A$25.23M
For detailed information about AT1 stock, go to TipRanks’ Stock Analysis page.